Sana Biotechnology, Inc. - Common Stock, par value $0.0001 per share (SANA)

Historical Holders from Q1 2021 to Q4 2025

Symbol
SANA on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
266,434,249
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
163,623,611
Holdings value
$580,877,242
% of all portfolios
0%
Number of holders
177
Number of buys
110
Number of sells
56
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sana Biotechnology, Inc. - Common Stock, par value $0.0001 per share (SANA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARCH Venture Fund IX, L.P. 17% $163,630,594 46,093,125 Robert Nelsen 30 Sep 2025
BlackRock, Inc. 4.9% $19,407,853 11,027,189 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 4.8% $18,916,058 10,747,760 The Vanguard Group 31 Dec 2024
As of 30 Sep 2025 Sana Biotechnology, Inc. - Common Stock, par value $0.0001 per share (SANA) has 177 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 163,623,611 shares of 266,434,249 outstanding shares and own 61% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Sana Biotechnology, Inc. - Common Stock, par value $0.0001 per share (SANA) own 56% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Holdings Value Nb Shares Share Change %
FMR LLC 14% $132,881,346 37,431,365 +11%
Flagship Pioneering Inc. 9.4% $88,756,589 25,001,856 0%
BAILLIE GIFFORD & CO 4.3% $40,599,586 11,436,503 +14%
BlackRock, Inc. 4.2% $39,852,782 11,226,136 +3.4%
CANADA PENSION PLAN INVESTMENT BOARD 3.8% $36,121,250 10,175,000 0%
VANGUARD GROUP INC 3.4% $32,407,854 9,128,973 +20%
STATE STREET CORP 2.5% $23,715,921 6,680,541 +134%
CITADEL ADVISORS LLC 2.5% $23,259,519 6,551,977 +122%
Marex Group plc 1.4% $13,570,869 3,822,780 +0.13%
GEODE CAPITAL MANAGEMENT, LLC 1.3% $12,155,856 3,423,532 +4.4%
Alphabet Inc. 1.1% $9,984,375 2,812,500 0%
JPMORGAN CHASE & CO 0.8% $7,580,826 2,135,444 +181%
BAKER BROS. ADVISORS LP 0.76% $7,209,869 2,030,949 0%
Integral Health Asset Management, LLC 0.75% $7,100,000 2,000,000 +33%
RENAISSANCE TECHNOLOGIES LLC 0.75% $7,073,375 1,992,500 +878%
Crestline Management, LP 0.68% $6,464,326 1,820,937 -25%
MILLENNIUM MANAGEMENT LLC 0.61% $5,751,000 1,620,000 +103%
UBS Group AG 0.54% $5,126,150 1,443,986 +26%
Woodline Partners LP 0.52% $4,892,738 1,378,236 +76%
NORTHERN TRUST CORP 0.49% $4,680,661 1,318,496 +14%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.48% $4,517,599 1,272,563 +17%
AQR CAPITAL MANAGEMENT LLC 0.44% $4,195,328 1,181,782 -13%
BANK OF AMERICA CORP /DE/ 0.34% $3,257,628 917,642 +3.7%
MORGAN STANLEY 0.33% $3,111,593 876,505 -41%
Omega Fund Management, LLC 0.32% $2,995,313 843,750 0%

Institutional Holders of Sana Biotechnology, Inc. - Common Stock, par value $0.0001 per share (SANA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 10,657 $44,622 +$44,622 $4.13 2
2025 Q3 163,623,611 $580,877,242 +$66,215,019 $3.55 177
2025 Q2 145,529,650 $398,240,759 -$12,602,312 $2.73 153
2025 Q1 149,116,670 $250,511,096 -$14,520,097 $1.68 156
2024 Q4 157,927,058 $257,416,034 -$1,264,160 $1.63 158
2024 Q3 153,070,144 $636,844,420 +$15,469,267 $4.16 154
2024 Q2 148,181,280 $809,095,908 -$349,502 $5.46 149
2024 Q1 5,838,884 $58,387,367 +$5,986,757 $10.00 13
2023 Q4 78,220 $329,938 -$46,868 $4.22 2
2023 Q3 127,224,368 $492,369,952 -$30,210,236 $3.87 130
2023 Q2 134,614,817 $802,298,695 +$25,709,331 $5.96 119
2023 Q1 130,459,977 $426,581,510 +$6,801,018 $3.27 116
2022 Q4 128,317,982 $506,822,179 +$988,224 $3.95 116
2022 Q3 127,456,132 $764,600,931 +$15,334,212 $6.00 115
2022 Q2 124,575,071 $800,976,039 +$45,788,573 $6.43 106
2022 Q1 117,559,300 $970,495,531 +$27,758,718 $8.26 105
2021 Q4 110,407,255 $1,709,226,718 +$21,638,668 $15.48 97
2021 Q3 109,950,783 $2,477,138,522 +$266,078,026 $22.52 88
2021 Q2 64,059,271 $1,259,280,145 +$104,914,085 $19.66 77
2021 Q1 58,277,853 $1,950,554,711 +$1,950,554,479 $33.47 75